DVL2 Knockout A2780 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population in which the DVL2 gene has been disrupted, providing a loss-of-function model for investigating Wnt signaling. Derived from the A2780 human ovarian carcinoma line, this polyclonal population retains epithelial characteristics while lacking functional DVL2, enabling dissection of DVL2-dependent pathways. The polyclonal nature offers diverse editing events, suitable for population-based studies without single-cell cloning biases.
The A2780 cell line is a well-characterized human ovarian endometrioid adenocarcinoma model, established from an untreated patient with cisplatin-sensitive disease. As an epithelial ovarian cancer line, A2780 cells are employed in cancer biology, drug screening, and signal transduction research. Their intrinsic platinum sensitivity provides a context for evaluating how Wnt pathway perturbations influence chemotherapeutic responses in an oncogenic background.
DVL2 functions as a critical scaffold protein relaying signals from Frizzled receptors and LRP5/6 to multiple pathways. Upon Wnt ligand (e.g., Wnt3a, Wnt5a) binding, DVL2 is recruited to the membrane, polymerizes, and interacts with the ??-catenin destruction complex (AXIN1, APC, CK1, GSK3??) to disassemble it, stabilizing ??-catenin. Nuclear ??-catenin partners with TCF/LEF to activate targets like MYC and CCND1. DVL2 also signals to planar cell polarity via RhoA and Rac1, activates JNK and CaMKII/NFAT, and cross-talks with the Hippo pathway, demonstrating its regulatory breadth.
In A2780 ovarian cancer cells, DVL2 knockout uncouples Wnt-dependent proliferation, migration, and survival from the oncogenic network. This model is valuable for examining DVL2??s role in ovarian carcinoma progression and testing Wnt-targeted therapeutics. By eliminating endogenous DVL2, one can assess the impact on ??-catenin-responsive transcription, epithelial-mesenchymal transition, and cisplatin sensitivity, linking DVL2 function to clinically relevant phenotypes.
Applications include RT-qPCR of Wnt targets (MYC, CCND1), Western blotting for ??-catenin and DVL2, immunofluorescence for ??-catenin localization, and TOPFlash reporter assays. The polyclonal cells are suited for high-content Wnt modulator screening, proliferation (MTT) and migration assays, co-immunoprecipitation of DVL2 partners (AXIN1, GSK3??, ??-arrestin), and RNA-seq. These support mechanistic studies and drug discovery against Wnt-driven cancers. For further information, contact Ascent Research.
